Ethereum plans to activate its major Glamsterdam upgrade on the Sepolia testnet on October 6, 2026, introducing Enshrined Proposer-Builder Separation (ePBS) to increase block capacity and transaction processing time. However, developers have raised security concerns about potential attacks where fake builder accounts could disrupt block building by winning bids but withholding transaction data, risking testnet paralysis. Development teams must release Sepolia-compatible software by September 29, with further testing on the Hoodi testnet expected by October 27. The mainnet launch is targeted for Q4 2026 but remains unconfirmed.
Ethereum's upcoming Glamsterdam testnet upgrade is noted alongside a strong market breadth where 46 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 18, 2026 14:31 WIB: CAKE (PancakeSwap) rose 8.28% to Rp44.013 with a typical hold time of 75 days and order activity showing 57% sell and 43% buy; THETA (Theta Network) increased 8.22% to Rp3.448 with 100% buy order activity and a 77-day hold; SAND (The Sandbox) gained 8.17% to Rp661 with a typical hold time of 123 days and 60% buy activity.
Gulfport Energy's Vice President, Willrath, sold 325 shares of the company's stock, generating $59,400 from the transaction. This insider sale may indicate personal financial decisions or portfolio adjustments but does not necessarily reflect the com...
NEAR Protocol's token surged 45% from $2.34 to $3.45 within three days, driven by the launch of confidential perpetual trading via Hyperliquid and a new rewards initiative called Push to $3.33. The platform now supports private leveraged trading acro...
LB Pharmaceuticals received a buy rating with a base valuation of $85 per share and potential upside to $150 if its Phase 3 clinical trials and drug differentiation succeed. The key drug, LB-102, shows promise due to its effective brain receptor targ...
TransMedics is experiencing a slowdown in liver transplant growth, increasing its reliance on international markets and other organ transplants like heart, lung, and kidney to drive future growth. Delays in heart and lung clinical trials have created...
SK hynix is rated a strong buy as it transitions from cyclical commodity memory to a high-margin AI infrastructure business. Strategic moves like a KRW 40 trillion share cancellation, new product launches (HBF and SALT-KV), and long-term agreements o...
